Market closed
ProQR Therapeutics/PRQR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ProQR Therapeutics
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.
Ticker
PRQR
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
-
Website
PRQR Metrics
BasicAdvanced
$282M
Market cap
-
P/E ratio
-$0.29
EPS
0.39
Beta
-
Dividend rate
Price and volume
Market cap
$282M
Beta
0.39
52-week high
$4.04
52-week low
$1.11
Average daily volume
2.5M
Financial strength
Current ratio
2.73
Quick ratio
2.701
Long term debt to equity
39.806
Total debt to equity
58.41
Interest coverage (TTM)
-25.04%
Management effectiveness
Return on assets (TTM)
-13.28%
Return on equity (TTM)
-50.39%
Valuation
Price to revenue (TTM)
16.443
Price to book
8.58
Price to tangible book (TTM)
8.58
Price to free cash flow (TTM)
-9.192
Growth
Revenue change (TTM)
290.57%
Earnings per share change (TTM)
-61.53%
3-year revenue growth (CAGR)
107.88%
3-year earnings per share growth (CAGR)
-35.53%
What the Analysts think about PRQR
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for ProQR Therapeutics stock.
PRQR Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
PRQR Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
PRQR News
AllArticlesVideos
ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement
GlobeNewsWire·1 day ago
ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement
GlobeNewsWire·4 days ago
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
GlobeNewsWire·4 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for ProQR Therapeutics stock?
ProQR Therapeutics (PRQR) has a market cap of $282M as of October 26, 2024.
What is the P/E ratio for ProQR Therapeutics stock?
The price to earnings (P/E) ratio for ProQR Therapeutics (PRQR) stock is 0 as of October 26, 2024.
Does ProQR Therapeutics stock pay dividends?
No, ProQR Therapeutics (PRQR) stock does not pay dividends to its shareholders as of October 26, 2024.
When is the next ProQR Therapeutics dividend payment date?
ProQR Therapeutics (PRQR) stock does not pay dividends to its shareholders.
What is the beta indicator for ProQR Therapeutics?
ProQR Therapeutics (PRQR) has a beta rating of 0.39. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.